Literature DB >> 30236512

The first prospective trial for von Hippel-Lindau disease: pazopanib.

Rachel H Giles1, Sven Gläsker2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30236512     DOI： 10.1016/S1470-2045(18)30533-3

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  2 in total

1.  Neuroendocrine neoplasms - think about it and choose the most appropriate diagnostic and therapeutic steps.

Authors:  Christian A Koch; S Petersenn
Journal:  Rev Endocr Metab Disord       Date:  2018-06       Impact factor: 6.514

2.  The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease.

Authors:  A M Cuesta; V Albiñana; E Gallardo-Vara; L Recio-Poveda; I de Rojas-P; K Villar Gómez de Las Heras; D T Aguirre; L M Botella
Journal:  Sci Rep       Date:  2019-07-11       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.